DNAJC5 and malaria: RTS, S in combination with AS01 (RTS, S/AS01) generated stronger CSP-specific humoral and cellular immune responses [28,29], offered protection from experimental Plasmodium sporozoite challenges and was the first malaria vaccine to enter Phase III clinical trials [30].